biostudies-literatureBhat KNIAID NIH HHSNCI NIH HHSNIAID8-15https://www.ebi.ac.uk/biostudies/studies/S-EPMC6400303biostudies-literatureUnknown132OBJECTIVE:Exposure to lethal doses of radiation has severe effects on normal tissues. Exposed individuals experience a plethora of symptoms in different organ systems including the gastrointestinal (GI) tract, summarized as Acute Radiation Syndrome (ARS). There are currently no approved drugs for mitigating GI-ARS. A recent high-throughput screen performed at the UCLA Center for Medical Countermeasures against Radiation identified compounds containing sulfonylpiperazine groups with radiation mitigation properties to the hematopoietic system and the gut. Among these 1-[(4-Nitrophenyl)sulfonyl]-4-phenylpiperazine (Compound #5) efficiently mitigated gastrointestinal ARS. However, the mechanism of action and target cells of this drug is still unknown. In this study we examined if Compound #5 aRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology1-(4-nitrobenzenesulfonyl)-4-penylpiperazine increases the number of Peyer's patch-associated regenerating crypts in the small intestines after radiation injury.PMC6400303U19 AI067773P50 CA211015R01 CA200234U19 AI067769AI067769Ramanathan RDuhachek-Muggy SSaki MDamoiseaux RPajonk FBhat KMcBride WHAlli CWhitelegge JSchaue DMedina PVlashi Efalse1-(4-nitrobenzenesulfonyl)-4-penylpiperazine increases the number of Peyer's patch-associated regenerating crypts in the small intestines after radiation injury.OBJECTIVE:Exposure to lethal doses of radiation has severe effects on normal tissues. Exposed individuals experience a plethora of symptoms in different organ systems including the gastrointestinal (GI) tract, summarized as Acute Radiation Syndrome (ARS). There are currently no approved drugs for mitigating GI-ARS. A recent high-throughput screen performed at the UCLA Center for Medical Countermeasures against Radiation identified compounds containing sulfonylpiperazine groups with radiation mitigation properties to the hematopoietic system and the gut. Among these 1-[(4-Nitrophenyl)sulfonyl]-4-phenylpiperazine (Compound #5) efficiently mitigated gastrointestinal ARS. However, the mechanism of action and target cells of this drug is still unknown. In this study we examined if Compound #5 a2019-01-01T00:00:00Z2019 Mar2025-04-22T03:03:23.544Z2020-05-22T11:33:21ZS-EPMC64003033082597410.1016/j.radonc.2018.11.011